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OBJECTIVES We tested the hypothesis that different anticoagulant treatments may produce different
platelet effects and von Willebrand factor (vWf) release in unstable angina.
BACKGROUND The early increase of vWf has been reported to be a risk factor for adverse outcome in unstable
angina. Anticoagulant drugs play a key role in stabilization of unstable angina, but they may
not have the same efficacy and the same effects on acute vWf release.
METHODS We studied 154 patients enrolled in several clinical trials testing four different anticoagulant
treatments in unstable angina or non-Q-wave myocardial infarction. Patients were treated
during at least 48 h by either intravenous unfractionated heparin, one of two different low
molecular weight heparins (enoxaparin or dalteparin) or the direct thrombin inhibitor
PEG-hirudin. All patients received aspirin but no IIb/IIIa inhibitors.
RESULTS The release of vWf over the first 48 h (D vWf) did not relate to the baseline clinical
characteristics. At 30 days of follow-up, D vWf was sevenfold higher in patients with an end
point (death, myocardial infarction, revascularization) than in patients free of events (153 6
7% vs. 17 6 14%, p 5 0.004). The same trend was present for each component of the
composite end point with the highest levels for one-month mortality (187 6 32% vs. 126 6
8%, p 5 0.09). The vWf values did not increase over 48 h in patients receiving either
enoxaparin or PEG-hirudin (110 6 9% and 25 6 20%, respectively). A serious rise of vWf
was measured in unfractionated heparin-treated patients (187 6 11%), which differed
significantly from the enoxaparin group (p 5 0.0006) and PEG-hirudin group (p , 0.0001).
In dalteparin-treated patients, D vWf was elevated (148 6 8%) and did not differ from the
unfractionated heparin group (NS).
CONCLUSIONS We confirm that, in unstable angina patients, a rise of vWf over the first 48 h is associated
with an impaired outcome at 30 days. Moreover, the four different anticoagulant treatments
tested here do not provide the same protection with regards to vWf release, which may have
important prognostic implications and explain different results observed in recent clinical
trials. (J Am Coll Cardiol 2000;36:110–4) © 2000 by the American College of Cardiology
In recent years, the management of patients with unstable
angina has greatly improved in both risk stratification and
drug therapy. Few biochemical markers bring additive
prognosis information to what is known from medical
history, symptoms, and electrocardiogram (ECG); tro-
ponins, C-reactive protein, fibrinogen or von Willebrand
factor (vWf) can participate to a better risk stratification of
patients. We recently reported the predictive value for
adverse outcome at one-month of an early rise of vWf in
unstable angina patients recruited in a substudy of the
ESSENCE trial (1). Furthermore, a treatment effect was
present with less release of vWf on enoxaparin than on
unfractionated heparin treatment, but several questions
remained unanswered. We did not know whether it was a
specific property of enoxaparin or a low molecular weight
heparin class effect, or even a common characteristic of
anticoagulant treatments clinically more effective than un-
fractionated heparin in unstable angina.
To date, only two anticoagulant drugs have shown
superior results to unfractionated heparin in unstable an-
gina: the low molecular weight heparin enoxaparin in both
ESSENCE and TIMI-11B (Thrombolysis in Myocardial
Infarction) trials and, the direct thrombin inhibitor lepiru-
din in OASIS 1 and 2 trials (2–5). Dalteparin, a different
low molecular weight heparin, has shown equivalent results
to unfractionated heparin (6). The increase of vWf being a
predictor of clinical outcome in unstable angina, we hypoth-
esized that its control may relate to the efficacy of antico-
agulation and differ between the various anticoagulant
treatments evaluated in unstable angina. We decided to
measure vWf release over the first 48 h of treatment in
unstable angina patients receiving four different anticoagu-
lant therapies: continuous IV unfractionated heparin ad-
justed to activated partial thromboplastin time (aPTT),
enoxaparin given subcutaneously twice daily, dalteparin
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given subcutaneously twice daily, and continuous IV. PEG-
hirudin, a direct thrombin inhibitor with a favorable phar-
macologic profile, tested successfully in a phase II trial (7).
The vWf, a multimeric protein of the acute-phase reac-
tion, is stored in the Weibel-Palade bodies of endothelial
cells and in the platelet alpha-granules and can be released
rapidly at the local site of the injured artery; vWf is crucial
for both platelet adhesion to exposed subendothelium and
platelet aggregation. Recently, in the plasma of patients
with acute myocardial infarction, increased vWf plasma
concentrations was the main determinant for the enhance-
ment of platelet aggregation at high shear rates (8). The
vWf plasma levels, heightening shear-induced aggregation,
may have a causative role in acute coronary thrombotic
events. Furthermore, epidemiological studies have shown
vWf to be a risk factor for coronary heart disease, and
elevated levels have been measured in acute coronary situ-
ations like myocardial infarction, unstable angina and cor-
onary angioplasty (1,9–12). Release of vWf in unstable
angina reflects the seriousness of the platelet-mediated
event, and its relation to anticoagulant treatment is a real
issue for this new marker of prognosis (1).
METHODS
Study population. We studied 154 patients with unstable
coronary artery disease defined as rest angina lasting more
than 10 min, with the last episode of chest pain within the
last 24 h, and clear evidence of coronary artery disease as
shown by at least one of the following: 1) ECG changes; 2)
a rise of creatine kinase (CK) and/or troponin I; 3) previous
myocardial infarction, percutaneous transluminal coronary
angioplasty (PTCA) or coronary artery bypass graft
(CABG); 4) previous positive exercise test; and 5) previous
coronary angiography showing a significant stenosis of any
coronary artery.
Exclusion criteria included persistent ST-segment eleva-
tion, contraindications to anticoagulation, current need for
oral anticoagulant (e.g., heart valve prosthesis), and severe
renal failure.
The study patients were enrolled in different centers
participating in trials (TIMI-11B, ESSENCE, USIC-
registry, PEGHIRUD 022) that evaluated low molecular
weight heparins, PEG-hirudin and unfractionated heparin
in unstable angina. Therefore, patients were not directly
randomized among the four treatment groups, but there was
no bias in the allocation to the different anticoagulant
treatments. In all these trials, anticoagulation was always
administered for a minimum of 48 h, and the last blood
sampling was always obtained on treatment. Informed
consent was obtained from all patients, and the study was
approved by the Human Research Committee of the Insti-
tutional Review Board.
Study design. All patients were treated with aspirin (100 to
325 mg daily), beta-blockers and IV nitrates unless contra-
indicated. None of the patients received IIb/IIIa inhibitors.
Anticoagulation was performed with either unfractionated
heparin, enoxaparin, dalteparin, or PEG-hirudin. Patients
treated with unfractionated heparin received an IV bolus
(5,000 IU) followed by a continuous infusion at a dose
adjusted to the activated partial-thromboplastin time, tar-
geting values between 1.5 and 3.0 times control (according
to the study). Enoxaparin was given at a dose of 100 anti-Xa
units/kg, subcutaneously at 12-h intervals. Dalteparin was
administered at a dose of 120 anti-Xa units/kg, subcutane-
ously at 12-h intervals. Escalating doses of PEG-hirudin
were used (phase II trial), combining a bolus dose of
0.1 mg/kg with an infusion of 0.02, 0.025, 0.03 or 0.035
mg/kg/h IV. Doses of PEG-hirudin were not adjusted to
aPTT; however, for safety reasons the upper limit of aPTT
was set at 3.0 times control and the infusion was stopped in
case the patient exceeded the set limit. Infusion was re-
started immediately after the aPTT was below 3.0 times
control (aPTT being rechecked every 2 h).
End points were evaluated at 30 days, including death,
new myocardial infarction or revascularization procedure.
For the purpose of the present study, we used the database
of each trial in which patients were enrolled, with all
demographic data, baseline characteristics, validated clinical
events and revascularisation procedures. We evaluated each
individual end point as well as the triple end point combin-
ing death, myocardial infarction, revascularization proce-
dures, and the double end point associating death and
myocardial infarction.
Antigen measurements of vWf. Blood was sampled twice
in each patient on admission (baseline) and at 48 h. Venous
blood (9 volumes) was collected into a Vacutainer tube
containing 0.129 mol/liter trisodium citrate (1 volume) for
vWf antigen measurements. Platelet-poor plasma was ob-
tained by centrifugation at 3000g for 20 min at 10°C.
Plasma was aliquoted and stored at 280°C. Frozen samples
were transported in dry ice from each center to the central
laboratory, and the quality of frozen samples was checked on
delivery. All measurements were performed in a blinded
fashion in the central laboratory of Pitie´-Salpe´trie`re Hospi-
tal. As previously described, the plasma concentrations of
vWf antigen were measured in duplicate with an enzyme-
linked immunosorbent assay (ELISA) technique (Asserach-
rom vWf, Diagnostica Stago, Asnie`res, France) (12). The
enzyme immunoassay procedure was controlled as recom-
mended by the manufacturer. The normal range of the
laboratory evaluated in healthy volunteers was 60% to 110%.
The interassay and intraassay coefficient of variation was
Abbreviations and Acronyms
aPTT 5 activated partial thromboplastin time
CABG 5 coronary artery bypass graft
CK 5 creatine kinase
ECG 5 electrocardiogram
PTCA 5 percutaneous transluminal coronary
angioplasty
vWf 5 von Willebrand factor
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,5%. Changes of vWf over 48 h (D vWf) were calculated as
D vWf 5 vWf at H48 2 vWf at Ho (baseline).
Statistical analysis. Results are expressed as mean 6 SEM.
Simple linear regression was used to test the association
between continuous variables. Potential associations be-
tween clinical or biological parameters were tested by
univariate procedures using the Student t or chi-square
tests, with an alpha level set at 0.05. The significance of
differences among different treatment groups were deter-
mined by analysis of variance (ANOVA) and post hoc t tests
with Bonferroni correction, the level of significance being
p 5 0.0083 after correction for the multiple comparisons.
RESULTS
Clinical characteristics. We recruited 154 patients into
this study. Thirty-nine patients were assigned to unfraction-
ated heparin (69% men, mean age 68 6 2 years), 44 to
PEG-hirudin (72% men, mean age 61 6 2 years), 40 to
enoxaparin (58% men, mean age 69 6 2 years) and 31 to
dalteparin (66% men, mean age 66 6 2 years). Thirty-four
patients (22%) were more than 75 years old. The admission
diagnosis was unstable angina in 113 patients (73%) and
non-Q-wave myocardial infarction in 41 patients (27%).
Changes in ECG were present in 125 patients (81%).
Forty-three patients (28%) had a prior history of myocardial
infarction, 12 patients (8%) had a prior CABG, 27 patients
(18%) had a prior PTCA, and the distribution of baseline
clinical characteristics was similar in the four treatment
groups. Complete clinical follow-up at 30 days was obtained
in 150 patients (98%). At one month, death occurred in 8
patients (5%), myocardial infarction in 12 patients (8%) and
revascularization (PTCA and/or CABG) in 59 patients
(38%). At least one clinical end point (death, myocardial
infarction, or revascularization) occurred in 68 patients
(44%), while death or myocardial infarction occurred in 17
patients (11%) within the first month.
Release of vWf and baseline characteristics. Mean vWf
plasma level of the entire study population was 199 6 10%
at baseline and increased further to 230 6 9% at 48 h. The
vWf levels at baseline and at 48 h as well as the release over
the first 48 h (D vWf) did not relate significantly to any of
the baseline clinical characteristics. The D vWf did not
correlate with age, but there was a trend to higher D vWf
values in patients over 70 years (Table 1). Similarly, a slight
but nonsignificant increase of D vWf was measured in
patients with a prior history of myocardial infarction, a prior
CABG, or a non-Q-wave myocardial infarction (compared
to unstable angina), all characteristics usually associated
with an impaired prognosis (Table 1).
Effects of anticoagulant treatments on vWf release. The
early rise of vWf measured in unfractionated heparin-
treated patients was not observed in the two groups of
unstable angina patients treated with either PEG-hirudin or
enoxaparin (see Fig. 1). In contrast, an early increase of vWf
was present in dalteparin-treated patients, which did not
differ significantly from the rise measured in the unfraction-
ated heparin group, although of smaller magnitude.
Over the first two days, vWf increased in 83% of patients
who experienced a clinical event within the 30 days of
follow-up. The D vWf was sevenfold higher in patients with
an end point (death, myocardial infarction, revasculariza-
tion) at one month than in those free of end point (p 5
0.004; see Fig. 2). The same trend was present for each
component of the composite end point; seven patients died
between 48 h and one month with D vWf peaking at 87 6
32% in these eight patients (p 5 0.09 vs. the rest of the
population).
In each treatment group, mean D vWf was always higher
in patients with an event compared to those free of events at
one-month follow-up. Mean D vWf values were particularly
low in patients without events treated with either PEG-
hirudin or enoxaparin (225 6 34% and 0 6 10% in
PEG-hirudin and enoxaparin groups, respectively). In con-
trast, mean D vWf was 27 6 7% in patients with a favorable
Table 1. Von Willebrand Factor Release and Clinical
Characteristics of Patients
D von Willebrand
Factor (%) p Value
Males 25 6 9 NS
Females 42 6 15
Age , 70 yrs 16 6 11 NS
Age . 70 yrs 48 6 10
No prior MI 23 6 9 NS
Prior MI 47 6 15
No prior CABG 28 6 8 NS
Prior CABG 65 6 18
No ECG changes 29 6 9 NS
ECG changes 30 6 9
Unstable angina 24 6 9 NS
Non-Q-wave MI 41 6 16
MI: myocardial infarction; CABG: coronary artery bypass graft.
Figure 1. Absolute changes of von Willebrand factor levels over 48 h in
patients receiving either enoxaparin, unfractionated heparin, PEG-hirudin,
or dalteparin. Differences among treatment groups were analyzed by
ANOVA and post hoc t tests with Bonferroni correction for multiple
comparisons: after correction, comparisons were significant if p value was
less than 0.0083. D von Willebrand factor was significantly lowered with
PEG-hirudin and enoxaparin compared to unfractionated heparin.
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one-month outcome treated with dalteparin (vs. 56 6 10%
for dalteparin-treated patients with an event).
DISCUSSION
We confirm in this study that vWf is released acutely during
the first 48 h of unstable angina and that an early and
important rise of vWf is associated with an adverse outcome
at one-month follow-up. The most important finding,
however, is the different control of vWf release obtained
with four different anticoagulant regimens. The direct
thrombin inhibitor PEG-hirudin and the low molecular
weight heparin enoxaparin were the most effective in lim-
iting acute release of vWf. Our results shed light on an
important marker of risk in unstable angina, on the platelet
stimulating effects of some anticoagulants, and on possible
explanations for diverging clinical results observed in several
trials performed with these anticoagulant treatments.
Low molecular weight heparins in unstable angina. Four
major clinical trials have now compared three different low
molecular weight heparins to unfractionated heparin in
unstable angina: two trials have demonstrated consistently
the superiority of enoxaparin over unfractionated heparin
(2,3), whereas two others have shown equivalent results
between the low molecular weight heparins (dalteparin or
nadroparin) and unfractionated heparin (6,13). These ap-
parent discrepancies cannot be really explained by different
levels of anti-Xa activity as enoxaparin, nadroparin, and
dalteparin have anti-Xa:anti–IIa ratios of 3:1, 3:1, and 2:1,
respectively. The decreased binding to plasma proteins, the
better bioavailability, and the resistance to platelet factor 4
are other advantages of low molecular weight heparins over
unfractionated heparin, but they do not differ much between
various low molecular weight heparins. In contrast, the
different types of heparin appear to activate platelets to
different degrees (14–19). In vitro studies have documented
the enhancement of platelet aggregation with heparin
(16,18,20), and Xiao and Theroux (21) have shown differ-
ences of platelet stimulation between unfractionated heparin
and enoxaparin in 43 unstable angina patients, but no
relationship to clinical outcome was reported. We demon-
strate here that D vWf, a marker of both platelet stimulation
and adverse clinical outcome, is reduced by enoxaparin in
comparison to unfractionated heparin, which documents a
better control of the platelet–endothelium interaction with
enoxaparin, an effect less apparent with dalteparin in similar
conditions.
The vWf and thrombin inhibition in unstable angina.
The vWf mediates platelet adhesion to sites of vascular
damage through the glycoprotein-Ib receptor, acts as a
platelet agonist, and binds to glycoprotein-IIb/IIIa receptor,
facilitating platelet aggregation (22,23). Moreover, vWf is
bound to factor VIII, protecting it from inactivation and
delivering it at the sites of the damaged vessel (24). More
vWf provides more factor VIIIa available for both Xa and
thrombin generation. Thrombin plays a pivotal role in the
thrombotic process through its numerous activating effects
on coagulation and platelets. Thrombin is a major agonist of
both endothelial cells and platelets, then causing more vWf
release from these activated cells. Our data obtained with
PEG-hirudin, a direct thrombin inhibitor with long-lasting
effects, confirm further the hypothesis that a good control of
thrombin is associated with little vWf release, an indicator
of favorable outcome at one-month follow-up.
Our data are also consistent with the platelet effects
measured ex vivo with another direct thrombin inhibitor
(argatroban) (21) and with the clinical results of recent trials
opposing hirudin to unfractionated heparin in unstable
angina. In OASIS-2, lepirudin was superior to unfraction-
ated heparin in preventing death and myocardial infarction
at day 3, which was confirmed at days 7 and 35 with a
combined analysis of OASIS-1 and -2 trials (4,5). The
preliminary short-term results obtained with PEG-hirudin
opposed to unfractionated heparin in a phase-2 trial showed
similar trends with a 62% reduction of death and myocardial
infarction (NS) and a 75% reduction of the triple end point,
including revascularizations (p 5 0.03) (7).
Anticoagulants and vWf release in unstable angina. The
platelet effects of heparins have gained little attention in the
management of unstable angina, and the proaggregant
effects of unfractionated heparin, despite the use of aspirin,
may well be clinically relevant, contributing to refractory
ischemia or rebound effect after heparin discontinuation
(25). Release of vWf seems to be a good marker of the
control exerted by anticoagulant treatments on platelet
activation as well as a marker of prognosis. Such a marker
may help identify high-risk patients and control the efficacy
obtained with the new standards of anticoagulation in
unstable angina. The main limitation of our study is the lack
of randomization among the four treatment groups; how-
ever, our patients were enrolled in various randomized trials
testing the different anticoagulants, and biological analyses
Figure 2. The rise of von Willebrand factor over the first 48 h identified
high-risk patients with a significant difference after univariate comparisons
(p , 0.05) between patients with an end point and those free of end points
at one-month follow-up. A similar trend was present for each parameter of
the composite end point. Checkered bars 5 patients free of event at 30
days; Open bars 5 patients with an event at 30 days.
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were blinded for clinical outcome and treatment allocation.
Our ongoing French multicenter ARMADA trial random-
izes unstable angina patients to receive either unfractionated
heparin, enoxaparin, or dalteparin and will examine the vWf
hypothesis as a secondary end point of the study.
Conclusions. In summary, the early increase of vWf in
unstable angina patients treated with unfractionated heparin
is blunted by PEG-hirudin or enoxaparin but little reduced
by dalteparin. Considering the pathogenetic role and prog-
nostic value of vWf, this platelet effect may be an important
explanation for the superiority observed with enoxaparin
and direct thrombin inhibitors in clinical trials.
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